Tech Company Financing Transactions
Accuitis Funding Round
Accuitis, based in Alpharetta, secured $1 million in funding from BioMed Ventures and GRA Venture Fund.
Transaction Overview
Company Name
Announced On
11/24/2015
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Undisclosed
Investors
BioMed Ventures (Lead Investor) (Geoffrey Meacham)
Proceeds Purpose
A startup out of the Emory Univerity tech transfer office, the company intends to use the funds for continue development of its topical proteasome inhibitor (ACU-D1) for the treatment of Rosacea into Phase 1-2 clinical trials in 2016.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1005 Alderman Dr. 104
Alpharetta, GA 30024
USA
Alpharetta, GA 30024
USA
Phone
Website
Email Address
Overview
Accuitis is engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Coulon
Chief Financial Officer
Michael Shippel
Chief Operating Officer
Jack Arbiser
Browse more venture capital transactions:
Prev: 11/24/2015: Lenda venture capital transaction
Next: 11/24/2015: Quizlet venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs